

## KEY TERMS OF CEO APPOINTMENT

**Perth, Australia, 8 November 2016:** On 3 November 2016, Australian life sciences company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) announced the appointment of Dr Learne Hinch as Chief Executive Officer of the Company.

As required under Listing Rule 3.16.4, the summary of key terms of Learne's Employment Agreement are as follows:

Position	<ul style="list-style-type: none"> <li>▪ Chief Executive Officer (CEO).</li> </ul>
Total Fixed Remuneration (TFR)	<ul style="list-style-type: none"> <li>▪ \$300,000 pa (inclusive of Salary and Superannuation) during the probation period, and then \$350,000 pa thereafter.</li> </ul>
Short Term Incentive (STI)	<ul style="list-style-type: none"> <li>▪ Eligible for STI of up to 40% of TFR at the end of each 12 month period.</li> <li>▪ Payment based on achievement of key performance indicators (KPIs) to be set and agreed between the Board and CEO during the Probationary Period.</li> </ul>
Long Term Incentive (LTI)	<ul style="list-style-type: none"> <li>▪ Eligible for LTI, subject to shareholder approval and other requirements.</li> <li>▪ Grant of 20,000,000 Options for Ordinary Shares in the Company issued in 4 tranches over 3 years with a 4-year expiry that shall vest as follows:               <ol style="list-style-type: none"> <li>1. 5M issued @ 5cps upon appointment at completion of the Probationary Period</li> <li>2. 5M issued @ 5cps upon achieving Milestone 1</li> <li>3. 5M issued @ 6cps upon achieving Milestone 2</li> <li>4. 5M issued @ 7cps upon achieving Milestone 3</li> </ol> </li> <li>▪ Issue based on meeting agreed milestones to be set and agreed between the Board and CEO during the Probationary Period.</li> <li>▪ Vesting subject to the Executive remaining in the employ of the Company at each vesting date.</li> </ul>
Term	<ul style="list-style-type: none"> <li>▪ No fixed term.</li> <li>▪ Probation period of 3 months.</li> </ul>
Termination	<ul style="list-style-type: none"> <li>▪ Without cause, subject to Notice Period by either Party.</li> <li>▪ For cause, immediate dismissal.</li> </ul>
Notice Period	<ul style="list-style-type: none"> <li>▪ 6 months.</li> </ul>
Commencement Date	<ul style="list-style-type: none"> <li>▪ Monday, 7 November 2016.</li> </ul>

- ENDS -

**FOR MORE INFORMATION, PLEASE CONTACT:**

**Peter Gunzburg**  
Executive Chairman  
E [peter@bard1.com](mailto:peter@bard1.com)  
M +61 412 927 773

**Dr Leearne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416

**ABOUT BARD1 LIFE SCIENCES LTD**

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer. Its proprietary BARD1 Technology is a potent tumour suppressor in healthy individuals and important tumour biomarker in cancer. Its lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer. It is also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients' lives.